Press release
Deadline in Lawsuit for Investors in shares of Iterum Therapeutics plc (NASDAQ: ITRM) coming up on October 4th
A Deadline is coming up on October 4, 2021 in the lawsuit for certain investors in Iterum Therapeutics plc (NASDAQ: ITRM).
Investors who purchased shares of Iterum Therapeutics plc (NASDAQ: ITRM) have certain options and there are strict and short deadlines running. Deadline: October 4, 2021. NASDAQ: ITRM stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to the complaint filed in the U.S. District Court for the Northern District of Illinois the plaintiff alleges on behalf of purchasers of Iterum Therapeutics plc (NASDAQ: ITRM) common shares between November 30, 2020 and July 23, 2021, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between November 30, 2020 and July 23, 2021, the Defendants made false and/or misleading statements and/or failed to disclose that the sulopenem NDA lacked sufficient data to support approval for the treatment of adult women with uUTIs caused by designated susceptible microorganisms proven or strongly suspected to be non-susceptible to a quinolone, that accordingly, it was unlikely that the FDA would approve the sulopenem NDA in its current form, that Defendants downplayed the severity of issues and deficiencies associated with the sulopenem NDA, and that as a result, the Company's public statements were materially false and misleading at all relevant times.
Those who purchased shares of Iterum Therapeutics plc (NASDAQ: ITRM) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Deadline in Lawsuit for Investors in shares of Iterum Therapeutics plc (NASDAQ: ITRM) coming up on October 4th here
News-ID: 2392930 • Views: …
More Releases from Shareholders Foundation
Investigation announced for Long-Term Investors in shares of West Pharmaceutical …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of West Pharmaceutical Services, Inc..
Investors who are current long term investors in West Pharmaceutical Services, Inc. (NYSE: WST) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in (NYSE: WST stocks follows a lawsuit filed…
Investigation announced for Long-Term Investors in Open Lending Corporation (NAS …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Open Lending Corporation.
Investors who are current long term investors in Open Lending Corporation (NASDAQ: LPRO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: LPRO stocks follows a lawsuit filed against Open…
Investigation announced for Long-Term Investors in shares in BigBear.ai Holdings …
An investigation on behalf of current long-term investors in shares of BigBear.ai Holdings, Inc. (NYSE: BBAI) concerning potential breaches of fiduciary duties by certain directors and officers of BigBear.ai Holdings, Inc. was announced.
Investors who are current long term investors in BigBear.ai Holdings, Inc. (NYSE: BBAI) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm…
Lawsuit filed for Investors who lost money with shares of DoubleVerify Holdings, …
An investor, who purchased shares of DoubleVerify Holdings, Inc. (NYSE: DV), filed a lawsuit over alleged violations of Federal Securities Laws by DoubleVerify Holdings, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of DoubleVerify Holdings, Inc. (NYSE: DV) have certain options and for certain investors are short and strict deadlines running. Deadline: July 21, 2025. NYSE: DV investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for Iterum
Sulopenem Etzadroxil/Probenecid (orlynvah) by Iterum Therapeutics expected to ch …
Washington, D.C. - DelveInsight, a premier pharmaceutical market research firm, has launched its latest report, "Sulopenem Etzadroxil/Probenecid Market Size, Forecast, and Emerging Insight - 2032." This in-depth analysis delivers crucial insights into the evolving market landscape, clinical advancements, and regulatory trajectory of Sulopenem Etzadroxil/Probenecid-a groundbreaking treatment poised to redefine uncomplicated urinary tract infection (uUTI) management across key global markets.
Request for sample report @ https://www.delveinsight.com/report-store/sulopenem-etzadroxil-probenecid-emerging-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Addressing the Growing Burden of uUTIs
Urinary tract…
Sulopenem Etzadroxil/Probenecid Market Size and Share Analysis Across 7MM and Co …
DelveInsight has released a comprehensive report titled "Sulopenem Etzadroxil/Probenecid Market Forecast" offering a thorough examination and predictive insights into the Sulopenem Etzadroxil/Probenecid market landscape until 2032 across the seven major markets (7MM), encompassing the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
The extensive report offers a thorough examination of the market potential and market share of Sulopenem Etzadroxil/Probenecid in the therapeutics landscape for uncomplicated Urinary…
Carbapenem-Based Antibiotics Market Growth Status and Outlook 2023-2029 | ACS Do …
The qualitative report published by market intelligence data research on the "Carbapenem-Based Antibiotics Market offers an in-depth examination of the current trends, latest expansions, conditions, market size, various drivers, limitations, and key players along with their profile details. The Carbapenem-Based Antibiotics market report offers the historical data for 2017 to 2022 and also makes available the forecast data from the year 2023 to 2029 which is based on revenue. With…
Plant Stem Cell Market See Incredible Growth 2021-2028 | Shionogi Inc, Iterum Th …
𝐏𝐥𝐚𝐧𝐭 𝐒𝐭𝐞𝐦 𝐂𝐞𝐥𝐥 𝐌𝐚𝐫𝐤𝐞𝐭 top level players are analyzed in report based on current and future development status, and Plant Stem Cell market estimations from 2021 to 2028 in terms of revenue and volume. This report provides strategic recommendations consulted by the industrial experts including market share worldwide, future outlook, cost profit structure, supply, raw materials, labour cost, manufacturing expenses, latest market trends, demands, ROI.
The Plant Stem Cell market report…
Investigation announced for Long-Term Investors in shares of Iterum Therapeutics …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Iterum Therapeutics plc.
Investors who are current long term investors in Iterum Therapeutics plc (NASDAQ: ITRM) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: ITRM stocks follows a lawsuit filed against Iterum…
Lawsuit filed for Investors in Iterum Therapeutics plc (NASDAQ: ITRM) shares
An investor, who purchased shares of Iterum Therapeutics plc (NASDAQ: ITRM), filed a lawsuit in the U.S. over alleged violations of Federal Securities Laws by Iterum Therapeutics plc.
Investors who purchased shares of Iterum Therapeutics plc (NASDAQ: ITRM) have certain options and for certain investors are short and strict deadlines running. Deadline: October 4, 2021. NASDAQ: ITRM investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Ireland…
